VIRUS TODAY: 2nd vaccine draws closer to FDA approval

A second COVID-19 vaccine has won backing from a panel of experts

Virus Outbreak California
Virus Outbreak California

Here's what's happening Thursday with the coronavirus pandemic in the U.S.:

THREE THINGS TO KNOW TODAY

— A second COVID-19 vaccine moved closer to joining the U.S. fight against the pandemic as a panel of experts endorsed its safety and effectiveness, paving way for a final decision by the Food and Drug Administration on emergency use.

— An overwhelming amount of false information clung to COVID-19 as it circled the globe in 2020, from speculation that the coronavirus was created in a lab to hoax cures.

— The number of Americans applying for unemployment benefits rose again last week to 885,000, the highest weekly total since September, as a resurgence of coronavirus cases threatens the economy’s recovery from its springtime collapse.

THE NUMBERS: The seven-day rolling average for daily new deaths in the U.S. increased over the past two weeks from 1,606 on Dec. 2 to 2,570 on Wednesday, according to data from Johns Hopkins University.

DEATH TOLL: The U.S. death toll stands at 309,334 people, or about the population of St. Paul, Minnesota.

QUOTABLE: “This is coming much faster than what anybody thought. Something that might have otherwise taken several years — to take this new vaccine technology and test it and approve it — was compressed into within a year.” — Dr. Jesse Goodman of Georgetown University, former chief of the FDA s vaccine division.

ICYMI: The Associated Press' pandemic atlas offers a look at the coronavirus in the U.S. by the numbers.

ON THE HORIZON: The FDA’s green light for emergency use of the Moderna vaccine is expected quickly. Moderna would then begin shipping millions of doses, earmarked for health workers and nursing home residents, to boost the largest vaccination effort in U.S. history.

___

Find AP’s full coverage of the coronavirus pandemic at https://apnews.com/hub/coronavirus-pandemic

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in